ABSTRACT
The present manuscript describe simple, sensitive, rapid, accurate, precise and economical Q-absorbance ratio method for the simultaneous determination of Rifampicin and Piperine in combined capsule dosage form. Absorbance ratio method uses the ratio of absorbances at two selected wavelengths, one which is an isoabsorptive point and other being the λ-max of one of the two components. Rifampicin and Piperine show an isoabsorptive point at 387 nm in methanol. The second wavelength used is 337 nm, which is the λ-max of Piperine in methanol. The linearity was obtained in the concentration range of 5-40 μg/ml for Rifampicin and 2-20 μg/ml for Piperine. The concentrations of the drugs were determined by using ratio of absorbances at isoabsorptive point and at the λ-max of Rifampicin. The method was successfully applied to pharmaceutical dosage form because no interference from the capsule excipients was found. The results of analysis have been validated statistically and by recovery studies.
ABSTRACT
The present manuscript describe simple, sensitive, rapid, accurate, precise and economical Q-absorbance ratio method for the simultaneous determination of cefpodoxime proxetil and ofloxacin in combined tablet dosage form. Absorbance ratio method uses the ratio of absorbances at two selected wavelengths, one which is an isoabsorptive point and other being the λ-max of one of the two components. Cefpodoxime proxetil and ofloxacin show an isoabsorptive point at 273.2 nm in methanol. The second wavelength used is 297 nm, which is the λ-max of ofloxacin in methanol. The linearity was obtained in the concentration range of 2-14 μg/ml for both cefpodoxime proxetil and ofloxacin. The concentrations of the drugs were determined by using ratio of absorbances at isoabsorptive point and at the λ-max of ofloxacin. The method was successfully applied to pharmaceutical dosage form because no interference from the tablet excipients was found. The results of analysis have been validated statistically and by recovery studies.
ABSTRACT
A simple and sensitive spectrofluorimetric method has been developed for the determination of deflazacort in pharmaceutical tablet dosage forms. The method was based on the liebermann-burchard reaction, in which the chloroform extract of deflazacort is reacted with acetic anhydride and sulfuric acid to produce strong fluorescence. The resulting fluorophor exhibit excitation and emission wavelengths at 300 and 435 nm, respectively. Linear relationship for the fluorescence intensity was obtained in the concentration range of 0.5 - 10 μg/ml. The method was validated in terms of linearity (0.5-10 μg/ml), repeatability (RSD, 0.99 %), precision (intra-day variation, RSD, 0.239 to 1.287 % and inter-day variation, RSD, 0.360 to 1.830 %) and accuracy (99.12 to 100.28 %). The limit of detection and limit of quantification for deflazacort were found to be 0.15 and 0.45 85.70 μg/ml, respectively. The developed method was successfully used for the assay of deflazacort tablet formulation. The spectrofluorimetric method was found to be simple, sensitive, accurate, precise and economic and can be used for the routine quality control testing of deflazacort in tablet dosage form.
ABSTRACT
The present manuscript describes simple, sensitive, rapid, accurate, precise and economic dual wavelength spectrophotometric method for simultaneous determination of metoprolol succinate and olmesartan medoxomil in combined tablet dosage form. The utility of dual wavelength data processing program is its ability to calculate unknown concentration of components of interest in a mixture containing an interfering component. The principle for dual wavelength method is “the absorbance difference between two points on the mixture spectra is directly proportional to the concentration of the component of interest”. The wavelengths selected for determination of metoprolol succinate were 225.2 nm and 258.2 nm, whereas the wavelengths selected for determination of olmesartan medoxomil were 211 nm and 229.8 nm. The two drugs follow Beer-Lambert’s law over the concentration range of 5-30 μg/ml. The method was successfully applied to pharmaceutical dosage form because no interference from the tablet excipients was found. The results of analysis have been validated statistically and by recovery studies.
ABSTRACT
A simple and sensitive high performance thin layer chromatography (HPTLC) method has been developed for the quantitative estimation of deflazacort in its single component tablet formulation (30 mg). Deflazacort was chromatographed on silica gel 60 F254 TLC plate using benzene: methanol: glacial acetic acid (7.5:2.0:0.5, v/v/v) as mobile phase. Deflazacort showed Rf value of 0.60 + 0.02 and scanned at 243 nm using a camag TLC scanner 3. The method was validated in terms of linearity (100 – 800 ng/spot), precision (intra-day variation, 0.335 to 1.203% and inter-day variation, 0.231 to 1.471%), accuracy (98.87 to 99.77%) and specificity. The limit of detection and limit of quantification for deflazacort were found to be 25.97 ng/spot and 85.70 ng/spot, respectively. The developed method was successfully used for the assay of deflazacort tablet formulation. The method was found to be simple, sensitive, specific, accurate and precise and can be used for the routine quality control testing of deflazacort in tablet dosage form.